Skip to content

Novavax NVAX Current maturities of long-term debt

Current maturities of long-term debt at other companies

Moderna logo
ModernaMRNA
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's current maturities of long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's current maturities of long-term debt?
Novavax (NVAX) reported current maturities of long-term debt of $2.11M in Q1 2026.
How has Novavax's current maturities of long-term debt changed year-over-year?
Novavax's current maturities of long-term debt decreased by 61.4% year-over-year, from $5.48M to $2.11M.
What is the long-term trend for Novavax's current maturities of long-term debt?
Over 5 years (2020 to 2025), Novavax's current maturities of long-term debt has grown at a -52.7% compound annual growth rate (CAGR), from $105.86M to $2.51M.